Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145755 | 1.00 | KMT2A (0.64) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145665 | 0.90 | MEN1 (0.66) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145663 | 0.90 | MEN1 (0.66) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145649 | 0.89 | KMT2A (0.60) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145647 | 0.89 | KMT2A (0.60) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145654 | 0.89 | NPC1 (0.65) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145656 | 0.89 | NPC1 (0.65) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145667 | 0.88 | KMT2A (0.64) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21145668 | 0.88 | KMT2A (0.64) | KMT2AMEN1NPC1KLF5L3MBTL1 | |
| SCHEMBL21192742 | 0.85 | MEN1 (0.78) | KMT2AMEN1NPC1KLF5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | KMT2A 585/4885MEN1 4774/4885NPC1 1570/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | KMT2A 585/4885MEN1 4774/4885NPC1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.